NCT03723044

Brief Summary

Some stimuli, such as sinusoidal networks in motion, or the best known, Necker's cube, are simple visual stimulations generating interpretations of unstable and oscillatory shapes or movements, mutually exclusive. Currently, the explanatory models of these perception phenomena are based on adaptation and learning mechanisms as well as the importance of noise in the perceptual and decision-making system. Often noise is a harmful component, but it can also be a facilitator in perceptual systems: the investigator's eye is always in motion, it is the micro-movements during eye fixation (phase of eye stability). In particular, the role of micro-eye movements has been identified in perceptual systems, and it will be necessary here to relate these micro-movements to the perceptive tilts facing multisable stimuli. However, how to access the perceptive states is a real question, since it has been shown that the participant's transfer of his perceptual state by means of a motor response can alter the very state of the percept. This is why the EEG activity will be analyzed to learn to discriminate the different percepts over time, without disruption of the participant's perceptual exploration endogenous activity.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 22, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 29, 2018

Completed
1.6 years until next milestone

Study Start

First participant enrolled

June 5, 2020

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

January 17, 2024

Status Verified

January 1, 2024

Enrollment Period

4.9 years

First QC Date

October 22, 2018

Last Update Submit

January 15, 2024

Conditions

No Conditions

Keywords

Multistable PerceptionMicro eye movementElectroencephalography

Outcome Measures

Primary Outcomes (2)

  • Micro-eye movement

    Eye movements will be recorded with an eye-tracker : the continuous gaze position at each sampling period (1ms)

    along the complete experiment (2 hours) per session and per participant.

  • Electroencephalography

    EEG will be recorded with 64 scalp electrodes (sampling rate 1kHz) with alpha and gamma waveform to found synchronuous neural correlates with the peceptive changes.

    along the complete experiment (2 hours) per session and per participant.

Study Arms (1)

healthy volunteers

EXPERIMENTAL
Other: EEG and occulometry

Interventions

EEG and occulometryOTHER

Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).

healthy volunteers

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Signed informed consent
  • Medical examination carried out before the participation in the research
  • Age between 18 and 55 years
  • Minimum level of studies
  • Obligation to join the social security system
  • normal or corrected vision normal

You may not qualify if:

  • Subject included in another clinical and / or therapeutic experimentation in progress
  • Major vision disorder
  • Past or current neurological or neuropsychiatric pathologies
  • History of cranial trauma with loss of consciousness.
  • Medication treatments likely to modulate brain activity: benzodiazepine, antidepressants, neuroleptics, lithium, etc.
  • Diabetes, cardiac pathology, immunodeficiency.
  • Medication treatments likely to modulate the activity of the cardiovascular system.
  • History of abuse or recent ingestion of alcohol, hard drugs or doping products.
  • Consumption of more than 15 cigarettes per day
  • Subject deprived of liberty by a judicial or administrative decision (L1121-6 CSP)
  • Major subject subject to a legal protection measure or unable to express their consent (L1121-8 CSP)
  • Pregnant, parturient and nursing mothers (L1121-5)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Grenoble-Alpes

Grenoble, 38043, France

RECRUITING

Central Study Contacts

Anne Guerin, PhD

CONTACT

4 76 57 43 73anne.guerin@gipsa-lab.grenoble-inp.fr

Tiphaine Montagnon

CONTACT

tmontagnon@chu-grenoble.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 22, 2018

First Posted

October 29, 2018

Study Start

June 5, 2020

Primary Completion

May 1, 2025

Study Completion

May 1, 2025

Last Updated

January 17, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)